glp-1 ibd Frontiers GLP-1 based therapies and disease

In two Phase 2 clinical trials covering stasis and pressure ulcers, TB4 accelerated complete wound closure by almost a month in patients who achieved full healing one of the most substantial healing acceleration outcomes documented for a peptide compound in a controlled clinical investigation

The transactions closed, generating more than $1 billion used to pay down approximately 80% of then-outstanding obligations under the Credit Agreement

Additionally, 87% of participants were not using oral contraceptives at baseline

This dual action caught the attention of scientists studying wound healing, who began exploring whether these protective and regenerative properties could translate to skin repair applications

This is why subcutaneous delivery is at the moment the only feasible route for all GLP-1 receptor agonists